Last $142.71 USD
Change Today -0.66 / -0.46%
Volume 488.5K
BCR On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BCR) Snapshot

Open
$143.21
Previous Close
$143.37
Day High
$144.07
Day Low
$142.67
52 Week High
07/28/14 - $154.16
52 Week Low
10/3/13 - $113.52
Market Cap
10.7B
Average Volume 10 Days
480.3K
EPS TTM
$6.36
Shares Outstanding
74.6M
EX-Date
07/17/14
P/E TM
22.4x
Dividend
$0.88
Dividend Yield
0.60%
Current Stock Chart for CR BARD INC (BCR)

cr bard inc (BCR) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BCR) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular products, including percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. The company’s urology products include Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal; catheter stabilization devices; and products for therapeutic hypothermia. It also provides specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers and other diseases and disorders. In addition, the company offers surgical specialty products, such as implanted grafts and fixation devices for hernia and soft tissue repair products; surgical sealants for intraoperative sealing of air leaks in thoracic surgery; and other products that include irrigation, wound drainage, and original equipment manufacturers’ products. It sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities, as well as through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,000 Employees
Last Reported Date: 02/19/14
Founded in 1907

cr bard inc (BCR) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Group President
Total Annual Compensation: $660.0K
Group President
Total Annual Compensation: $560.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $540.0K
Compensation as of Fiscal Year 2013.

cr bard inc (BCR) Key Developments

3M Co, CareFusion Corp and C.R. Bard Eyes ConvaTec From Avista Capital Partners And Nordic Capital

3M Company (NYSE:MMM), CareFusion Corporation (NYSE:CFN) and C.R. Bard Inc. (NYSE:BCR) seeks to acquires ConvaTec Inc. from its private equity owners including Avista Capital Holdings, L.P and Nordic Capital, Reuters reported citing people familiar with the matter. The deal is believed to be explored by 2015. ConvaTec Inc. would review any compelling offer that would come before 2015. ConvaTec Inc., Avista Capital Holdings, L.P, Nordic Capital, 3M Company, CareFusion Corporation and C.R. Bard Inc could not be reached for comment.

CR Bard Inc. Presents at Piper Jaffray Heartland Summit 2014, Aug-06-2014

CR Bard Inc. Presents at Piper Jaffray Heartland Summit 2014, Aug-06-2014 . Venue: Minneapolis, Minnesota, United States. Speakers: Timothy M. Ring, Chairman, Chief Executive Officer and Chairman of Executive Committee.

CR Bard Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reports Asset Impairment Charges for the Second Quarter Ended June 30, 2014 ; Provides Earnings Guidance for the Third Quarter of 2014 ; Increases Earnings Guidance for the Full Year 2014

CR Bard Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of USD 119,400,000 or USD 1.59 per basic and diluted share on net sales of USD 827,100,000 compared to net loss of USD 161,600,000 or USD 2.03 per basic and diluted share on net sales of USD 759,900,000 for the last year. The company reported loss from operations before income taxes of USD 92,800,000 compared to USD 135,900,000 for the last year. Adjusted net income was USD 160,700,000 or USD 2.06 per diluted share against USD 131,700,000 or USD 1.59 per diluted share a year ago. Capital expenditures totaled USD 32.9 million for the quarter, and total debt was USD 1.6 billion as of June 30, compared to USD 1.4 billion at March 31, 2014. For the six months, the company reported net loss of USD 29,000,000 or USD 0.37 per diluted share on net sales of USD 1,626,400,000 compared to net income USD 70,900,000 or USD 0.88 per diluted share on net sales of USD 1,500,200,000 for the last year. The company reported income from operations before income taxes of USD 90,800,000 compared to loss from operations before income taxes USD 8,300,000 for the last year. Adjusted net income was USD 313,300,000 or USD 3.98 per diluted share against USD 267,000,000 or USD 3.20 per diluted share a year ago. For the second quarter of 2014, the company reported a charge of USD 3.2 million pre-tax related to asset impairment. For the third quarter of 2014, the company expected constant currency sales growth between 7% and 9%. The company expected continued improvement in organic sales growth rate through the rest of the year. From an EPS standpoint, excluding items affecting comparability, the company expected the third quarter in the range of USD 2.07 to USD 2.11 per share. For the full year 2014, the company expected constant currency sales growth to be between 8% and 9%. For the full year, the company increasing adjusted EPS guidance by USD 0.05, to USD 8.25 to USD 8.35 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCR:US $142.71 USD -0.66

BCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $45.25 USD -0.55
Edwards Lifesciences Corp $102.15 USD -1.02
Endo International PLC $68.34 USD -1.18
Varian Medical Systems Inc $80.12 USD -1.08
View Industry Companies
 

Industry Analysis

BCR

Industry Average

Valuation BCR Industry Range
Price/Earnings 14.6x
Price/Sales 3.4x
Price/Book 6.4x
Price/Cash Flow 13.6x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.